Avraham Sarit, Seidman Daniel S
IVF Unit, Department of Obstetrics and Gynecology, The Chaim Sheba Medical Center, The Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.
J Obstet Gynaecol India. 2012 Aug;62(4):386-90. doi: 10.1007/s13224-012-0309-7.
The modern era of infertility treatment was heralded over half a century ago with the introduction of new hormonal drugs that could effectively induce ovarian ovulation. However, it was quickly recognized that the birth of these new "miracle drugs" was associated with a remarkable increase in the incidence of high-order multiple births. Despite the fantastic improvement in our ability to monitor ovarian response during ovulation induction, and our power to control the number of embryos introduced into the womb through IVF, multiple births remain a leading cause of long-term child morbidity among infertility patients. Efforts to prevent what was coined in the 1960s as the "multiple birth epidemic" remain an urgent concern. A new body of research clearly points at our capacity to reduce the risk of multiple births and their associated long term morbidity without diminishing current high success rates of infertility treatment.
半个多世纪前,新型激素药物的问世开启了现代不孕症治疗的新纪元,这些药物能够有效诱导卵巢排卵。然而,人们很快就意识到,这些新型“神奇药物”的诞生伴随着高阶多胞胎出生率的显著上升。尽管我们在监测排卵诱导过程中卵巢反应的能力以及通过体外受精控制植入子宫的胚胎数量的能力有了惊人的提高,但多胞胎仍然是不孕症患者长期儿童发病的主要原因。防止20世纪60年代出现的“多胞胎流行”的努力仍然是一个紧迫的问题。一项新的研究明确指出,我们有能力降低多胞胎的风险及其相关的长期发病率,同时又不会降低目前不孕症治疗的高成功率。